title: Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.
abstract: BACKGROUND
  Information about the variation in the risk for venous thromboembolism (VTE) and in prophylaxis practices around the world is scarce. The ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study is a multinational cross-sectional survey designed to assess the prevalence of VTE risk in the acute hospital care setting, and to determine the proportion of at-risk patients who receive effective prophylaxis.
  
  
  METHODS
  All hospital inpatients aged 40 years or over admitted to a medical ward, or those aged 18 years or over admitted to a surgical ward, in 358 hospitals across 32 countries were assessed for risk of VTE on the basis of hospital chart review. The 2004 American College of Chest Physicians (ACCP) evidence-based consensus guidelines were used to assess VTE risk and to determine whether patients were receiving recommended prophylaxis.
  
  
  RESULTS
  68 183 patients were enrolled; 30 827 (45%) were categorised as surgical, and 37 356 (55%) as medical. On the basis of ACCP criteria, 35 329 (51.8%; 95% CI 51.4-52.2; between-country range 35.6-72.6) patients were judged to be at risk for VTE, including 19 842 (64.4%; 63.8-64.9; 44.1-80.2) surgical patients and 15 487 (41.5%; 41.0-42.0; 21.1-71.2) medical patients. Of the surgical patients at risk, 11 613 (58.5%; 57.8-59.2; 0.2-92.1) received ACCP-recommended VTE prophylaxis, compared with 6119 (39.5%; 38.7-40.3; 3.1-70.4) at-risk medical patients.
  
  
  CONCLUSIONS
  A large proportion of hospitalised patients are at risk for VTE, but there is a low rate of appropriate prophylaxis. Our data reinforce the rationale for the use of hospital-wide strategies to assess patients' VTE risk and to implement measures that ensure that at-risk patients receive appropriate prophylaxis.
authors.affiliation: King's College Hospital, London, UK. alexander.cohen@kcl.ac.uk
authors.forename: Alexander T
authors.initials: AT
authors.lastname: Cohen
authors.forename: Victor F
authors.initials: VF
authors.lastname: Tapson
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Bergmann
authors.forename: Samuel Z
authors.initials: SZ
authors.lastname: Goldhaber
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Kakkar
authors.forename: Bruno
authors.initials: B
authors.lastname: Deslandes
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.forename: Maksim
authors.initials: M
authors.lastname: Zayaruzny
authors.forename: Leigh
authors.initials: L
authors.lastname: Emery
authors.forename: Frederick A
authors.initials: FA
authors.lastname: Anderson
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D000075202:Contraindications; D003430:Cross-Sectional Studies; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006760:Hospitalization; D006801:Humans; D008297:Male; D008485:Medical Audit / Q000706:statistics & numerical data*; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants